Tendon injuries are among the most common injuries in sports activities. Most tendon injuries result from a tear in the tendon fibers due to overuse, aging, or accidents.
heal f recovery A torn tendon is notoriously difficult, and repairing a torn tendon often depends entirely on surgery. Tendon consists of cells (tendon fibroblasts) and an extracellular matrix, containing mostly type I collagen, type III collagen, and glycoproteins.
The tendon healing process is divided into three stages:
During the regeneration phase, tendon fibroblasts migrate infected site, proliferates and produces different types of collagen and glycoproteins to form the extracellular matrix. This is a lengthy process and the healed tendon is always weaker than the tendon before the injury .
Therefore, it is necessary to develop novel therapeutic approaches to accelerate healing and/or improve tendon strength.
BPC-157 is a 15-amino acid fragment of the body protecting complex (BPC) isolated from human gastric juice. .
It is stable and resistant to hydrolysis or digestion by enzymes, making it an extremely potent molecule. Previous studies have demonstrated the enhancing effect of BPC-157 on the healing of various tissues, including the skin, mucosa, and cornea, muscleand tendons, ligaments, and bones in animal studies .
Scientists consider it a blueprint for an entirely new class of organ preventative/therapeutic drugs, but the research is still in its early stages.
Mechanisms of action of BPC-157
BPC-157’s mechanism of action is likely to be in promoting muscle and tendon healing by stimulating the formation of new blood vessels – a process called angiogenesis (by increasing VEGF).
VEGF (vascular endothelial growth factor) originally known as vascular permeability factor, is a signaling protein produced by many cells that stimulates angiogenesis. This explains its ability to regenerate and why it may also help heal cuts, scrapes, and other types of damage to the body .
BPC-157 may promote wound and tendon healing by blocking the growth-suppressing effects of a specific molecule, called 4-hydroxynonenal. .
In addition, it may specifically aid tendon healing by causing tendon cells to make more receptors for growth-signaling molecules. In fact, this allows the tendon cells to grow and move while the injury is being repaired, thus speeding up recovery process .
It may also reduce inflammation, which likely plays a role in its effects on wounds, ulcers, and tissue protection .
Although the mechanisms of action of BPC-157 have not yet been fully elucidated, either in the current review or in other surrounding literature, some light has been shed on a few potential systems that include nitric oxide (NO)FAK-paxillin pathway, VEGF and growth hormone regulation (receptors) .
Healing of tendons and ligaments
Research proves it Injections of BPC-157 helped almost completely heal tendons in animals with Achilles tendon injuries.while the control animals did not fully recover .
BPC-157 appears to allow tendon fibroblasts to grow and proliferate faster, although this effect may not persist in fibroblasts alone, suggesting that other cells may be required for this effect or BPC-157 may act by negating suppressing factors. .
BPC-157 appeared to improve the rate of collagen remodeling after surgery, initially outperforming platelet growth factor after four days, but finally becoming isopotent after eight days. .
In fact, research indicates that BPC-157 can help with tendon regeneration after surgical damage. The peptide was also delivered via multiple pathways, indicating that the peptide has therapeutic utility via a wide range of delivery mechanisms (see figure below).
Form: examples of successful management mechanisms for delivering BPC 157; All methods, both local and systemic, have been reported to have positive therapeutic outcomes 
Skeletal muscle recovery
Similarly, peptide injections enhanced muscle healing from animals whose muscles had been cut or crushed. Interestingly, this effect was true when the animals were also given corticosteroids (such as hydrocortisone), which can slow down the healing process. .
This research group concluded that BPC-157 is able to improve wound healing and muscle contusion injury even in corticosteroid-treated rats.
BPC-157 completely reversed systemic corticosteroid impairment in muscle healing, modulating corticosteroid effects, and represents a potentially important peptide therapy.
Research also shows that besides improving function in muscles, BPC-157 also enhanced enzymatic activity by reducing muscle proteolysis. This mainly shows a decrease in skeletal muscle deterioration .
The authors concluded that BPC-157 accelerates skeletal muscle healing after injury as well as restoring full muscle function which is similar to the results found in tendons.
In addition to direct trauma induced muscle injuries, there have been several studies that have indicated that BPC-157 may have the potential to restore systemic muscular disorders in response to neurological and electrolyte induced disturbances and/or Skeletal muscle wasting .
Because systemic muscle pain is attributable to infection, autoimmune disease, illness, or medication side effects, it is considered to be more serious than stress or exercise-related muscle injuries.
Limitations of current research
Although the use of rodents and small mammals is traditional in research, particularly for the development of new therapeutic agents, caution must be exercised when extrapolating research data to clinical applications.
Despite the impressive results published so far, there remains a requirement to complete successful human trials before clinical translation. Since there are clear differences between rodent and human physiology, it cannot be ignored that this may have a significant impact on the efficacy and safety of (ie) new agents.
However, it is important to realize that BPC-157 is a peptide derived from human gastric juices and, therefore, a certain level of safety in people can be assumed.
However, this still cannot be considered a fact, therefore, due diligence must be undertaken to clarify whether the reported benefits of BPC-157 extend beyond research animals.
To date, research using BPC-157 as a therapeutic treatment has shown very positive healing effects for various types of injuries in many soft tissues.
But, At present, studies are mostly limited to small animal models (mostly from rodents) The effectiveness of BPC-157 has not yet been confirmed in humans.
Although more research is needed to better understand its mechanisms and efficacy in practical settings, BPC-157 has the potential to be developed as a novel therapy for conservative treatment or aiding in recovery after surgery in low vascular and low cellular soft tissues such as tendon tissues. and ligaments.
1. Yamaguchi, K., et al., Demographic and morphological features of rotator cuff disease. Comparison of asymptomatic and symptomatic shoulders. J Bone Joint Surgical Am, 2006. 88(8): p. 1699-704.
2. Bodis, B, et al., Evidence for a direct cellular protective effect of PL-10 substances (body protecting complex complex parts, BPC) and their specificity for gastric mucosal cells. Life Sciences, 1997. 61 (16): p. PL 243-8.
3. Chang, CH, et al., Pentadecapeptide BPC 157 enhances the expression of the growth hormone receptor in tendon fibroblasts. Molecules, 2014. 19 (11): p. 19066-77.
4. Krivic, A., et al., Modulation of early functional recovery of the Achilles tendon to bone unit after transection by BPC 157 and methylprednisolone. Inflamm Res, 2008. 57(5): p. 205-10.
5. Staresinic, M., et al., Gastrointestinal pentadecapeptide BPC 157 accelerates resected rat Achilles tendon healing and stimulates tendon cell growth in vitro. J Orthop Res, 2003. 21(6): p. 976-83.
6. Sikiric, P., et al., Stabilized gastric pentadecapeptide BPC 157: a novel gastrointestinal therapy. Core Pharm Dis, 2011. 17 (16): p. 1612-32.
7. Gwyer, D., N.M. Wragg, and S.L. Wilson, Gastric pentadecapeptide BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cellular Histology Res, 2019. 377 (2): p. 153-159.
8. Tkalcevic, VI, et al., Optimization by PL 14736 of granulocyte and collagen regulation in wound healing and the potential role of egr-1 expression. Eur J Pharmacol, 2007. 570 (1–3): p. 212-21.
9. Pevec, D., et al., Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application. Med Sci Monit, 2010. 16 (3): p. BR81-88.
10. Farges, MC, et al, Increased muscle proteolysis after posttraumatic trauma mainly reflects macrophage-associated lysosomal proteolysis. Am J Physiol Endocrinol Metab, 2002. 282 (2): p. E326-35.
11. Kang, EA, et al., BPC157 as a potential rescue agent for cancer cachexia. Core Pharm Dis, 2018. 24 (18): p. 1947-1956